stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Return on assets
Amylyx Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 June 2026 was −66.3%, down 11.2 percentage points from fiscal 2025 (−55.0%). Over the past ten years it has ranged from −599.6% (fiscal 2020) to 10.8% (fiscal 2023); the current reading is higher than 83% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −1.67% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −55.0% | 29.87 |
| FY2024 | −84.9% | (95.71) |
| FY2023 | 10.8% | 90.66 |
| FY2022 | −79.8% | 67.08 |
| FY2021 | −146.9% | 452.65 |
| FY2020 | −599.6% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LQDA Liquidia Corporation compare | 35.6% |
| SUPN Indivior Pharmaceuticals Inc. compare | 32.8% |
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| HIMS Hims & Hers Health, Inc. compare | −5.16% |
| TRLV Trulieve Cannabis Corp. compare | −17.6% |
| PRGO Perrigo Company plc compare | −20.2% |
| AMLX Amylyx Pharmaceuticals, Inc. | −66.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement